Kolexia
Recher Christian Hématologie
Recher Christian
Hématologie
Hôpital Purpan
Toulouse, France
615 Activités
7 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Lymphomes Lymphome B diffus à grandes cellules Lymphome B Maladie résiduelle Récidive tumorale locale

Collaborateurs

Voir plus
Pigneux Arnaud
Pigneux Arnaud
Hôpital Haut-lévêque, Pessac, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Bertoli Sarah
Bertoli Sarah
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Delabesse Eric
Delabesse Eric
Oncopole Toulouse, Toulouse, France

Industries

Voir plus
Abbvie
49 collaboration(s)
Dernière en 2023
Servier
32 collaboration(s)
Dernière en 2023
KEPHREN PUBLISHING
20 collaboration(s)
Dernière en 2023
Astellas
11 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Essai Clinique (Astellas)   21 mars 2024
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® That Targets CD123 and CD16A, in Patients With CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia
Essai Clinique (Affimed GmbH)   12 mars 2024
AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Essai Clinique (Servier)   01 mars 2024
LAM-RAPA: Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)
Essai Clinique (CHU Toulouse)   27 février 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation: A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation
Essai Clinique (Forma Therapeutics, Inc.)   18 février 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
American journal of hematology   11 février 2024
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
Essai Clinique (Celgene)   08 février 2024
Long-term survival of AML treated with intensive chemotherapy with extensive molecular data available.
Leukemia & lymphoma   08 février 2024
VOYAGE: A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Essai Clinique (MacroGenics)   24 janvier 2024